Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib.

British journal of haematology - 1 Jun 2023

Sarosiek Shayna, Gustine Joshua N, Flynn Catherine A, Leventoff Carly, Little Megan, White Timothy, Meid Kirsten, Treon Steven P, Castillo Jorge J

Abstract excerpt

Waldenström macroglobulinaemia (WM) is characterized by the presence of a MYD88L265P mutation. This mutation promotes growth and survival of malignant cells through Bruton tyrosine kinase (BTK) activation. Ibrutinib was the first BTK inhibitor approved for WM. Intolerance to ibrutinib frequently leads to dose reductions, though the impact of reducing ibrutinib dosing has not been systematically studied. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Waldenstrom Macroglobulinemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36626914
DOI: 10.1111/bjh.18643

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib.PMID 36626914Read ↗

Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.Semantic proximity Read ↗

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.Semantic proximity Read ↗

Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.Semantic proximity Read ↗

Emerging drugs for the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Current approach to Waldenström Macroglobulinemia.Semantic proximity Read ↗

How to Sequence Therapies in Waldenström Macroglobulinemia.Semantic proximity Read ↗

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Semantic proximity Read ↗

Advances in Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Novel Approaches in Waldenström Macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.